CN1733089A - 治疗糖尿病及并发症的药物及其制备方法 - Google Patents
治疗糖尿病及并发症的药物及其制备方法 Download PDFInfo
- Publication number
- CN1733089A CN1733089A CNA2005100357382A CN200510035738A CN1733089A CN 1733089 A CN1733089 A CN 1733089A CN A2005100357382 A CNA2005100357382 A CN A2005100357382A CN 200510035738 A CN200510035738 A CN 200510035738A CN 1733089 A CN1733089 A CN 1733089A
- Authority
- CN
- China
- Prior art keywords
- medicine
- group
- diabetes
- radix
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 184
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 91
- 229940079593 drug Drugs 0.000 title abstract description 30
- 238000004519 manufacturing process Methods 0.000 title abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 22
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 claims abstract description 14
- 241000208340 Araliaceae Species 0.000 claims abstract description 11
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 11
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 11
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 11
- 235000008434 ginseng Nutrition 0.000 claims abstract description 11
- 238000011282 treatment Methods 0.000 claims description 79
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 11
- 241001489978 Eupolyphaga Species 0.000 claims description 10
- 241000237903 Hirudo Species 0.000 claims description 10
- 241000237636 Pheretima Species 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 7
- 238000001694 spray drying Methods 0.000 claims description 7
- 238000007908 dry granulation Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 15
- 230000008569 process Effects 0.000 abstract description 3
- 241000208843 Arctium Species 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 241000131329 Carabidae Species 0.000 abstract 1
- 241000545744 Hirudinea Species 0.000 abstract 1
- 241000201320 Ligustrum japonicum Species 0.000 abstract 1
- 241000361919 Metaphire sieboldi Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 abstract 1
- 240000003582 Platycodon grandiflorus Species 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 54
- 210000004369 blood Anatomy 0.000 description 54
- 239000008280 blood Substances 0.000 description 54
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 37
- 230000000694 effects Effects 0.000 description 37
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 33
- 239000008103 glucose Substances 0.000 description 33
- 241001465754 Metazoa Species 0.000 description 32
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 30
- 239000006187 pill Substances 0.000 description 30
- 210000004185 liver Anatomy 0.000 description 26
- 210000002966 serum Anatomy 0.000 description 25
- 210000002784 stomach Anatomy 0.000 description 24
- 235000000346 sugar Nutrition 0.000 description 22
- 238000012360 testing method Methods 0.000 description 19
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 17
- 230000037396 body weight Effects 0.000 description 16
- 230000007812 deficiency Effects 0.000 description 16
- 102000004877 Insulin Human genes 0.000 description 15
- 108090001061 Insulin Proteins 0.000 description 15
- 229940125396 insulin Drugs 0.000 description 15
- 235000001727 glucose Nutrition 0.000 description 13
- 210000000056 organ Anatomy 0.000 description 13
- 210000003734 kidney Anatomy 0.000 description 12
- 238000011160 research Methods 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 229920002527 Glycogen Polymers 0.000 description 11
- 229940096919 glycogen Drugs 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 210000002700 urine Anatomy 0.000 description 11
- 230000003203 everyday effect Effects 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 230000003914 insulin secretion Effects 0.000 description 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 206010067482 No adverse event Diseases 0.000 description 7
- 210000004100 adrenal gland Anatomy 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 210000001541 thymus gland Anatomy 0.000 description 7
- 108010088751 Albumins Proteins 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 230000003907 kidney function Effects 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 230000001603 reducing effect Effects 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 210000001835 viscera Anatomy 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 206010013954 Dysphoria Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 238000004159 blood analysis Methods 0.000 description 5
- 206010016256 fatigue Diseases 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 230000035807 sensation Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000001550 testis Anatomy 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 231100000111 LD50 Toxicity 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 201000005577 familial hyperlipidemia Diseases 0.000 description 4
- 229930182494 ginsenoside Natural products 0.000 description 4
- 229940089161 ginsenoside Drugs 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 239000002547 new drug Substances 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 230000002110 toxicologic effect Effects 0.000 description 4
- 231100000027 toxicology Toxicity 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 102000051325 Glucagon Human genes 0.000 description 3
- 108060003199 Glucagon Proteins 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 3
- 229960004666 glucagon Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 230000002262 irrigation Effects 0.000 description 3
- 238000003973 irrigation Methods 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 231100001252 long-term toxicity Toxicity 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 238000003305 oral gavage Methods 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 206010036067 polydipsia Diseases 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- SJVJMFXCINSXFF-UHFFFAOYSA-N 5-(5-prop-1-ynylthiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C#CC)=CC=C1C1=CC=C(C(O)=O)S1 SJVJMFXCINSXFF-UHFFFAOYSA-N 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000007625 Hirudins Human genes 0.000 description 2
- 108010007267 Hirudins Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000007976 Ketosis Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010029240 Neuritis Diseases 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 229930183118 Tanshinone Natural products 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- BPYGTFFYYOWDBC-LOVSFRALSA-N arctiin Natural products COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc3ccc(O[C@@H]4O[C@H](C)[C@@H](O)[C@H](O)[C@H]4O)c(OC)c3)cc1OC BPYGTFFYYOWDBC-LOVSFRALSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 229940096998 ursolic acid Drugs 0.000 description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 1
- HCEQQASHRRPQFE-UHFFFAOYSA-N 5-chloro-n-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide;3-(diaminomethylidene)-1,1-dimethylguanidine;hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N.COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 HCEQQASHRRPQFE-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 241001417092 Macrouridae Species 0.000 description 1
- RINSJDWDXSWUOK-UHFFFAOYSA-N OC(=O)C1=CC=C(O)C(O)=C1.OC(=O)C1=CC=C(O)C(O)=C1 Chemical compound OC(=O)C1=CC=C(O)C(O)=C1.OC(=O)C1=CC=C(O)C(O)=C1 RINSJDWDXSWUOK-UHFFFAOYSA-N 0.000 description 1
- JLPDBLFIVFSOCC-UHFFFAOYSA-N Oleandrin Natural products O1C(C)C(O)C(OC)CC1OC1CC(CCC2C3(CC(C(C3(C)CCC32)C=2COC(=O)C=2)OC(C)=O)O)C3(C)CC1 JLPDBLFIVFSOCC-UHFFFAOYSA-N 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011697 diabetes animal model Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 229940112611 glucovance Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000004140 ketosis Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- STKUCSFEBXPTAY-YTECAPLWSA-N methyl (5e,6s)-5-ethylidene-4-[2-oxo-2-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[2-(4-hydroxyphenyl)ethoxy]oxan-2-yl]methoxy]ethyl]-6-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4h-pyran-3-carboxylate Chemical compound O([C@@H]\1OC=C(C(C/1=C\C)CC(=O)OC[C@@H]1[C@H]([C@H](O)[C@@H](O)[C@H](OCCC=2C=CC(O)=CC=2)O1)O)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O STKUCSFEBXPTAY-YTECAPLWSA-N 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- STKUCSFEBXPTAY-KCWGXYKVSA-N nuezhenoside Natural products COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C(=CC)[C@@H]1CC(=O)OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O STKUCSFEBXPTAY-KCWGXYKVSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- JLPDBLFIVFSOCC-XYXFTTADSA-N oleandrin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C[C@@H](CC[C@H]2[C@]3(C[C@@H]([C@@H]([C@@]3(C)CC[C@H]32)C=2COC(=O)C=2)OC(C)=O)O)[C@]3(C)CC1 JLPDBLFIVFSOCC-XYXFTTADSA-N 0.000 description 1
- 229950010050 oleandrin Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- IWZKICVEHNUQTL-UHFFFAOYSA-M potassium hydrogen phthalate Chemical compound [K+].OC(=O)C1=CC=CC=C1C([O-])=O IWZKICVEHNUQTL-UHFFFAOYSA-M 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 108700013750 rat Lyst Proteins 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 例数 | 性别 | 年龄病程 | ||||||
男 | 女 | 32~40 | 41~50 | 51~65 | 1~5 | 6~10 | 14~13 | ||
观察组对照组合计 | 200100300 | 13469203 | 663197 | 19827 | 9647143 | 8545130 | 10349152 | 6640106 | 311142 |
组别 | 例数 | 高脂血症 | 冠心病 | 高血压 | 视网膜病变 | 周围神经炎 |
观察组对照组 | 14074 | 50(35.7)26(35.1) | 40(28.6)22(29.7) | 12(8.6)7(9.5) | 23(164)13(17.6) | 15(10.7)6(8.1) |
组别 | 例数 | 显效 | 有效 | 无效 | 总有效率 |
观察组对照组 | 200100 | 99(495)52(52) | 78(39)35(35) | 23(11.5)13(13) | 177(88.5)87(87) |
组别 | 例数 | 显效 | 有效 | 无效 | 总有效率 |
观察组对照组 | 14074 | 27(19.3)10(13.5) | 88(62.9)39(52.7) | 25(17.9)25(33.8) | 98(82.1)49(66.2) |
观察组(200) | 对照组(100) | ||||||||
症状 | 消失 | 好转 | 无变化 | 有效率(%) | 消失 | 好转 | 无变化 | 有效率(%) | P值 |
口渴多饮 | 170 | 26 | 2 | 98.9 | 79 | 15 | 2 | 97.9 | >0.05 |
多食易饥 | 150 | 21 | 24 | 87.7 | 58 | 14 | 11 | 86.7 | >0.05 |
尿频量多 | 172 | 11 | 10 | 94.8 | 68 | 6 | 8 | 90.2 | >0.05 |
倦怠乏力 | 180 | 11 | 5 | 97.4 | 35 | 16 | 20 | 71.8 | <0.05 |
自汗 | 100 | 22 | 8 | 93.9 | 32 | 22 | 36 | 60.0 | <0.01 |
头晕 | 33 | 29 | 14 | 82.1 | 7 | 6 | 27 | 32.5 | <0.01 |
五心烦热 | 167 | 6 | 4 | 97.7 | 35 | 32 | 22 | 75.3 | <0.05 |
心悸 | 43 | 34 | 7 | 91.7 | 2 | 9 | 19 | 36.7 | <0.01 |
组别 | 例数 | 治疗前 | 治疗后 | 差值 |
观察组对照组 | 200100 | 15.45±4.1214.57±3.67 | 8.25±2.22※※7.56±2.15※※ | 7.24±1.12▲7.55±1.66▲ |
组别 | 例数 | 治疗前 | 治疗后 | 差值 |
观察组对照组 | 11060 | 12.95±2.2912.64±1.48 | 6.13±1.15※※6.33±1.37※※ | 6.45±1.13▲6.29±1.01 |
组别 | 例数 | 治疗前 | 治疗后 | 差值 |
观察组对照组 | 200100 | 5.863±1.2466.027±2.040 | 4.161±1.041※※5.312±1.345※ | 1.621±1.010▲0.566±0.414 |
组别 | 例数 | 治疗前 | 治疗后 | 差值 |
观察组对照组 | 200100 | 2.056±0.3592.134±0.278 | 1.471±0.120※※1.819±0.103※※ | 0.599±0.119▲▲0.302±0.112 |
测定时间 | 治疗前 | 治疗后 | P值 |
空腹1h2h3h | 16.97±6.7629.66±13.7638.55±16.2132.56±13.56 | 18.55±6.4540.45±16.3435.32±15.0722.17±9.78 | >0.05<0.05>0.05<0.05 |
组别 | 时间 | 全血粘度(mpa.s) | 血浆粘度(mpa.s) | 红细胞压积(%) | 纤维蛋白原(g/l) | 血沉K值(m/h) | |
高切 | 低切 | ||||||
观察组 | 疗前 | △△ | △△ | △ | △△ | △ | △ |
6.28±0.63 | 5.02±2.05 | 2.82±0.41 | 49.32±3.29 | 4.20±0.63 | 96.89±11.39 | ||
疗后 | ※※ | ※▲ | ※▲ | ※※▲▲ | ※※ | ※※▲ | |
5.68±0.38 | 13.78±1.49 | 2.15±0.34 | 45.47±3.68 | 3.24±0.69 | 84.13±7.29 | ||
对照组 | 疗前 | △△ | △ | △ | △△ | △ | △ |
3.19±0.59 | 15.23±2.23 | 2.68±0.64 | 49.54±4.31 | 3.75±0.75 | 95.89±9.57 | ||
疗后 | ※ | ※ | |||||
5.63±0.32 | 15.02±2.14 | 2.51±0.36 | 49.4g±4.82 | 3.14±0.43 | 92.39±11.67 | ||
健康对照 | 5.32±0.48 | 9.86±1.54 | 1.75±0.51 | 43.15±2.56 | 2.91±0.12 | 79.02±10.21 |
组别 | 例数 | 治疗前 | 治疗后 | 差值 |
正常对照组生理盐水组本药物组(高)本药物组(低)消渴丸组 | 10101099 | 537±0.6821.51±2.43※20.45±2.77※19.27±3.22※19.89±1.68※ | 5.43±0.72※※20.77±1.3110.32±2.06▲△○☆14.21±1.23▲△10.52±2.67▲△○ | 0.41±0.3810.32±0.21△○☆6.37±1.15△9059±0.72△○ |
组别 | 例数 | 肝糖元含量(mg/g湿重) |
正常对照组生理盐水组本药物组(高)本药物组(低)消渴丸组 | 10109109 | 19.52±6.4511.42±4.33※※18.51±5.31▲▲▲△16.59±3.45▲▲13.65±3.77▲ |
组别 | 例数 | 血清INS(mmol/L) |
正常对照组生理盐水这组本药物组(高)本药物组(低)消渴丸组 | 10109109 | 21.76±5.686.89±3.81※※14.76±2.59△△▲○11.23±3.24△15.64±2.56△△▲ |
组别 | n | 剂量(g/Kg) | 给药后 | ||
给药前 | 半个月 | 1个月 | |||
高剂量低剂量对照组 | 101010 | 3618- | 122.4±9.68*122.9±12.35*122.9±11.78 | 148.6±10.01*147.3±13.06*145.9±13.94 | 182.0±10.52*180.0±15.11*176.1±17.14 |
组别 | n | 剂量(g/Kg) | 心 | 肝 | 肺 | 肾(双) |
高剂量低剂量对照组 | 101010 | 3618- | 0.48±0.06*0.45±0.04*0.44±0.08 | 5.28±0.71*4.99±0.57*4.97±0.65 | 1.03±0.17*0.98±0.15*1.00±0.16 | 0.89±0.04*0.87±0.05*0.87±0.06 |
组别 | n | 剂量(g/Kg) | 脾(g/10吨) | 胸腺(g/100g) | 肾上腺(mg/100g) |
高剂量低剂量对照组 | 101010 | 3618- | 0.42±0.03*0.42±0.03*0.40±0.05 | 0.23±0.05*0.21±0.06*0.20±0.06 | 34.04±3.96*32.25±3.86*30.39±6.48 |
组别 | n | 剂量(g/Kg) | Hb(g/L) | RBC(×10.12/L) | BPC(×109/L) |
高剂量低剂量对照组 | 101010 | 3618- | 128.5±10.81*124.0±13.29*123.5±12.70 | 8.13±0.95*7.93±0.94*7.97±1.26 | 906.0±176.58*850.0±122.47*870.0±141.97 |
组别 | n | 剂量(g/Kg) | WBC(×109/L) | N(%) | L(%) |
高剂量低剂量对照组 | 101010 | 3618- | 8.96±1.69*8.36±1.50*8.61±1.23 | 60.7±6.52*65.2±6.89*65.3±5.21 | 39.3±6.52*34.8±6.8934.7±5.21 |
组别 | n | 剂量(g/Kg) | GPT(u/L) | GOT(u/L) | BUN(mmol/L) | Q(umol/L) |
高剂量低剂量对照组 | 101010 | 3618- | 51.4±6.45*52.5±5.64*53.5±5.10 | 156.5±17.06*164.1±18.15*165.5±10.99 | 7.14±0.49*6.94±0.48*6.98±0.44 | 105.5±14.45*10.54±10.83*112.3±12.16 |
组别 | n | 剂量(g/Kg) | ALP(u/L) | ch(mmol/L) | TBiL(mmol/L) |
高剂量低剂量对照组 | 101010 | 3618- | 180.9±27.05*175.4±17.41*167.4±11.15 | 1.59±0.29*1.56±0.26*1.58±0.20 | 6.47±0.51*6.35±0.46*6.46±0.44 |
组别 | n | 剂量(g/Kg) | 总蛋白(g/L) | 白蛋白(g/L) |
高剂量低剂量对照组 | 101010 | 3618- | 89.4±5.54*86.3±5.74*86.4±5.62 | 50.1±4.25*47.3±3.62*46.4±3.31 |
组别 | n | 剂量(g/Kg) | Hb(g/L) | RBC(×1012/L) | BPC(×109/L) |
高剂量低剂量对照组 | 101010 | 3618- | 127.0±11.35*124.5±10.66*122.0±11.11 | 7.77±1.22*8.16±1.05*7.40±0.98 | 782.0±101.19*768.0±110.53*760.0±93.81 |
组别 | n | 剂量(g/Kg) | WBC(×109/L) | N(%) | L(%) |
高剂量低剂量对照组 | 101010 | 3618- | 7.53±1.13*7.54±1.11*7.49±0.63 | 59.1±7.64*59.5±6.04*57.9±7.89 | 40.9±7.64*40.5±6.04*42.1±7.89 |
组别 | n | 剂量(g/Kg) | GPT(u/L) | GOT(u/L) | BUN(mmol/L) | CI(umol/L) |
高剂量低剂量对照组 | 101010 | 3618- | 50.8±3.94*50.5±5.30*51.2±4.31 | 150.2±13.64*153.5±12.49*157.6±13.46 | 6.62±0.55*6.63±0.48*6.61±0.41 | 107.3±15.00*108.9±11.62*114.7±11.65 |
组别 | n | 剂量(g/Kg) | ALP(u/L) | ch(mmol/L) | TBiL(mmol/L) |
高剂量低剂量对照组 | 101010 | 3618- | 150.2±13.57*147.2±22.26*153.3±14.17 | 1.54±0.17*1.55±0.16*1.63±0.23 | 6.87±6.12*7.61±0.61*6.99±0.66 |
组别 | n | 剂量(g/Kg) | 总蛋白(g/L) | 白蛋白(g/L) |
高剂量低剂量对照组 | 101010 | 3618- | 85.8±6.20*82.0±5.62*82.6±7.46 | 44.7±5.48*42.8±3.42*43.0±3.86 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100357382A CN1315499C (zh) | 2005-07-13 | 2005-07-13 | 治疗糖尿病及并发症的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100357382A CN1315499C (zh) | 2005-07-13 | 2005-07-13 | 治疗糖尿病及并发症的药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1733089A true CN1733089A (zh) | 2006-02-15 |
CN1315499C CN1315499C (zh) | 2007-05-16 |
Family
ID=36075844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100357382A Active CN1315499C (zh) | 2005-07-13 | 2005-07-13 | 治疗糖尿病及并发症的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1315499C (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101259158B (zh) * | 2007-03-05 | 2011-05-18 | 黑龙江省中医研究院 | 一种治疗冠心病的中药药物组合物及其制备方法 |
CN104436021A (zh) * | 2014-11-11 | 2015-03-25 | 成都华熹科技有限公司 | 一种含牛蒡子的治疗糖尿病的中药组合物 |
CN105999065A (zh) * | 2016-06-15 | 2016-10-12 | 唐家婷 | 一种治疗糖尿病的中药制剂及其制备方法 |
CN107536920A (zh) * | 2016-06-23 | 2018-01-05 | 上海医药集团股份有限公司 | 一种治疗周围神经炎的组合物、其制备方法和应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100195886B1 (ko) * | 1996-11-01 | 1999-06-15 | 김상조 | 당뇨병 치료용 의약조성물 |
CN1374093A (zh) * | 2001-03-14 | 2002-10-16 | 王书荣 | 一种治疗糖尿病的中药 |
-
2005
- 2005-07-13 CN CNB2005100357382A patent/CN1315499C/zh active Active
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101259158B (zh) * | 2007-03-05 | 2011-05-18 | 黑龙江省中医研究院 | 一种治疗冠心病的中药药物组合物及其制备方法 |
CN104436021A (zh) * | 2014-11-11 | 2015-03-25 | 成都华熹科技有限公司 | 一种含牛蒡子的治疗糖尿病的中药组合物 |
CN105999065A (zh) * | 2016-06-15 | 2016-10-12 | 唐家婷 | 一种治疗糖尿病的中药制剂及其制备方法 |
CN107536920A (zh) * | 2016-06-23 | 2018-01-05 | 上海医药集团股份有限公司 | 一种治疗周围神经炎的组合物、其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1315499C (zh) | 2007-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1565583A (zh) | 治疗糖尿病及其并发症的中药组合物 | |
CN1239183C (zh) | 一种中药组合物及其制备方法 | |
CN1132615C (zh) | 具有调节血糖功效的保健品及其制备方法 | |
CN1075735C (zh) | 治疗糖尿病的中药复方制剂及其制备方法 | |
CN1305405C (zh) | 一种能辅助降血糖、辅助降血脂的保健食品及其制备方法 | |
CN1557842A (zh) | 玉竹多糖的提取方法、药物制剂制备方法及其用途 | |
CN1733089A (zh) | 治疗糖尿病及并发症的药物及其制备方法 | |
CN1191082C (zh) | 一种治疗脂肪肝的中药组合物及其制备方法 | |
CN1246011C (zh) | 藕节提取物在制备改善人体胰岛素抵抗和治疗或预防肥胖症的药物中的应用 | |
CN1238024C (zh) | 治疗肾阳虚的中药及其制备方法 | |
CN1297290C (zh) | 一种治疗冠心病心绞痛的药物组合物及其制备方法 | |
CN100350940C (zh) | 治疗糖尿病及并发症的药物及其制备方法 | |
CN1831015A (zh) | 贞芪多糖的提取工艺及其产品和它的应用 | |
AU2015296844A1 (en) | Water extracts of cinnamon and Radix Astragali | |
CN1511583A (zh) | 月季花提取物及其制备方法和用途 | |
CN1319588C (zh) | 治疗高血脂、脂肪肝、肝纤维化的药物和制备方法 | |
CN1634463A (zh) | 治疗糖尿病的药物及生产方法 | |
CN1562113A (zh) | 一种治疗慢性***的药物及其制备方法 | |
CN1283300C (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
CN101062314A (zh) | 一种治疗痛风的药物及其制备方法 | |
CN1872321A (zh) | 一种治疗酒精性肝炎的中药组合物及其制备方法 | |
CN1726987A (zh) | 一种降血糖的中药组合物、制法及其鉴别方法 | |
CN1682934A (zh) | 玉泉浸膏及其药物组合物和用途 | |
CN1626103A (zh) | 一种含三七总皂苷和淫羊藿苷的药物组合物及其用途 | |
CN1562114A (zh) | 一种治疗慢性***炎的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU LANYUN MEDICINE RESEARCH CO., LTD. Free format text: FORMER OWNER: ZHANG JING Effective date: 20100831 |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510627 ROOM 601, NO.15, HUAJING ROAD, TIANHE DISTRICT, GUANGZHOU CITY, GUANGDONG PROVINCE TO: 510663 D909, INTERNATIONAL BUSINESS INCUBATOR ZONE D, NO.3, JUQUAN ROAD, SCIENCE CITY OF HIGH-TECH INDUSTRIAL DEVELOPMENT AREA, GUANGZHOU |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100831 Address after: 510663 high tech Industrial Development Zone of Guangzhou Science City skim Springs Road No. 3, Guangzhou international business incubator D D909 Patentee after: GUANGZHOU LANYUN MEDICINE RESEARCH Co.,Ltd. Address before: 510627 Guangdong city of Guangzhou province Tianhe District Hua Jing Lu No. 15 Room 601 Patentee before: Zhang Jing |
|
DD01 | Delivery of document by public notice |
Addressee: Zhang Jing Document name: Notification of Passing Examination on Formalities |
|
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: 510663 Guangdong city of Guangzhou province high tech Industrial Development Zone of Guangzhou Science City skim Springs Road No. 3, Guangzhou international business incubator B District 301 Patentee after: GUANGZHOU HONGYUN MEDICAL SCIENTIFIC AND TECHNOLOGICAL CO.,LTD. Address before: Guangzhou hi tech Industrial Development Zone, Science City skim Springs Road No. 3, Guangzhou international business incubator D D909 Patentee before: GUANGZHOU LANYUN MEDICINE RESEARCH Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20230629 Address after: 519000 Card slot 05, Room 408, Building 21, No. 1889 Huandao East Road, Hengqin New District, Zhuhai City, Guangdong Province Patentee after: Zhuhai Hengqin Hongtai Pharmaceutical Technology Co.,Ltd. Address before: 510663 No.301, zone B, Guangzhou International Business Incubator, No.3, Juquan Road, Science City, Guangzhou high tech Industrial Development Zone, Guangzhou City, Guangdong Province Patentee before: GUANGZHOU HONGYUN MEDICAL SCIENTIFIC AND TECHNOLOGICAL CO.,LTD. |
|
TR01 | Transfer of patent right | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: Building D, 2nd Floor, No. 1168 Huanli Road, Zhenmei Community, Xinhu Street, Guangming District, Shenzhen City, Guangdong Province, 518107 Patentee after: Hongtai (Shenzhen) Pharmaceutical Technology Co.,Ltd. Address before: 519000 Card slot 05, Room 408, Building 21, No. 1889 Huandao East Road, Hengqin New District, Zhuhai City, Guangdong Province Patentee before: Zhuhai Hengqin Hongtai Pharmaceutical Technology Co.,Ltd. |